November 18, 2024 – Singapore – EpiMedtech Global, a leader in genetic and epigenetic testing, is proud to announce that
Discover the groundbreaking high-throughput test developed by HKG Epitherapeutics and partners for the early detection of Hepatocellular Carcinoma. Utilizing distinctive
EpiMedTechGlobal (EMTG)
60 Paya Lebar Road,
#08-06 Paya Lebar Square
Singapore 409051
Honk Kong Lab
Unit 313-315, 3/F Biotech Centre 2
11 Science Park West Avenue
Hong Kong Science Park
US Epitherapeutics
1829 Reisterstown Rd, Suite: 350
Baltimore, MD 21208
+1 (443) 256 5179
MTL Epitherapeutics
600 – 2000 AV McGill College Montreal, QC CA H3A3H3
+1 (514) 448 2185
Shenzhen Lab
Zone E, Floor 4, Building E, Gangzhilong Business Center,
Qinglong Road, Longhua District, Shenzhen
Hong Kong: +(852) 60725262 USA: +1 (443) 256 5179 Canada: +1 (514) 448 2185
Founded in 2016 by Prof. Moshe Szyf, a global pioneer in the dynamic and rapidly evolving field of epigenetics, EpiMedTechGlobal (EMTG) stands as a force driving innovation. Officially headquartered in Singapore, our organization directs a state-of-the-art research and diagnostic lab located in Hong Kong, which serves as the epicenter of our groundbreaking endeavors. Here, our dedicated scientists are committed to driving innovation in epigenetics and the early detection of diseases. At EMTG, it’s not just about detecting diseases; it’s about unlocking and offering solutions that promote longevity through the hidden stories in our DNA.
©2023, EpiMedTechGlobal. All Rights Reserved.
